Talphera Advances Nafamostat Study Amid Rising CRRT Market Projections
With enrollment for its NEPHRO CRRT clinical trial reaching 75 percent, Talphera is moving toward a year-end conclusion for its nafamostat development program. The company reports that updated market research now projects 200,000 annual U.S. procedures for the therapy, marking a significant 21 percent increase over previous estimates.























